A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

NCT02284568 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

374

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Progressive Multiple Sclerosis

Interventions

DRUG: Placebo
DRUG: Laquinimod
DRUG: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.